- Home
- HIX vs RGNX Comparison
HIX vs RGNX Comparison
Compare HIX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIX
- RGNX
- Stock Information
- Founded
- HIX 1998
- RGNX 2008
- Country
- HIX United States
- RGNX United States
- Employees
- HIX N/A
- RGNX N/A
- Industry
- HIX Finance/Investors Services
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HIX Finance
- RGNX Health Care
- Exchange
- HIX Nasdaq
- RGNX Nasdaq
- Market Cap
- HIX 382.6M
- RGNX 387.0M
- IPO Year
- HIX N/A
- RGNX 2015
- Fundamental
- Price
- HIX $4.24
- RGNX $8.61
- Analyst Decision
- HIX
- RGNX Strong Buy
- Analyst Count
- HIX 0
- RGNX 8
- Target Price
- HIX N/A
- RGNX $31.75
- AVG Volume (30 Days)
- HIX 449.5K
- RGNX 1.2M
- Earning Date
- HIX 01-01-0001
- RGNX 07-31-2025
- Dividend Yield
- HIX 13.14%
- RGNX N/A
- EPS Growth
- HIX N/A
- RGNX N/A
- EPS
- HIX N/A
- RGNX N/A
- Revenue
- HIX N/A
- RGNX $156,718,000.00
- Revenue This Year
- HIX N/A
- RGNX $327.08
- Revenue Next Year
- HIX N/A
- RGNX N/A
- P/E Ratio
- HIX N/A
- RGNX N/A
- Revenue Growth
- HIX N/A
- RGNX 80.70
- 52 Week Low
- HIX $4.16
- RGNX $5.04
- 52 Week High
- HIX $5.08
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- HIX 57.93
- RGNX 45.54
- Support Level
- HIX $4.18
- RGNX $7.82
- Resistance Level
- HIX $4.26
- RGNX $8.61
- Average True Range (ATR)
- HIX 0.03
- RGNX 0.79
- MACD
- HIX -0.00
- RGNX -0.19
- Stochastic Oscillator
- HIX 72.22
- RGNX 21.66
About HIX Western Asset High Income Fund II Inc.
Western Asset High Income Fund II Inc is a diversified closed-end management investment company. Its investment objective is to maximize current income by investing at least 80% of its net assets and borrowings for investment purposes in high-yield debt securities.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.